RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.
Health organizations collaborate to address idiopathic pulmonary fibrosis on Rare Disease Day 2025
The American College of Chest Physicians (CHEST), the PF Warriors, the Rare Disease Diversity Coalition (RDDC)-a program at the Black Woman’s Health Imperative-and the National